LOG IN
SIGN UP
MARKET
ACER
ACER
Acer Therapeutics Inc
NASDAQ
Real-time Quotes | Nasdaq Last Sale
1.280
+0.020
+1.59%
After Hours: 1.300 +0.02 +1.56% 18:07 07/01 EDT
OPEN
1.260
PREV CLOSE
1.260
HIGH
1.280
LOW
1.203
VOLUME
15.39K
TURNOVER
0
52 WEEK HIGH
3.770
52 WEEK LOW
1.163
MARKET CAP
19.60M
P/E (TTM)
-0.9186
1D
5D
1M
3M
1Y
5Y
New Strong Sell Stocks for June 28th
ACER, BA, and LOB have been added to the Zacks Rank #5 (Strong Sell) List on June 28, 2022.
Zacks · 4d ago
BRIEF-Acer Therapeutics Announces Initiation Of Its Pivotal Phase 3 Discover Trial Of Edsivo (Celiprolol) For The Treatment Of Vascular Ehlers-Danlos Syndrome
BRIEF-Acer Therapeutics Announces Initiation Of Its Pivotal Phase 3 Discover Trial Of Edsivo (Celiprolol) For The Treatment Of Vascular Ehlers-Danlos Syndrome
Reuters · 5d ago
Acer Therapeutics begins phase 3 trial of Edsivo to treat rare genetic disorder treatment
Acer Therapeutics (NASDAQ:ACER) said on Monday it had begun patient screening in its Phase 3 trial of Edsivo to treat patients with COL3A1-positive vascular Ehlers-Danlos Syndrome (vEDS), a rare genetic disorder
Seekingalpha · 5d ago
Acer Therapeutics Announces Initiation of its Pivotal Phase 3 DiSCOVER Trial of EDSIVO™ (celiprolol) for the Treatment of Vascular Ehlers-Danlos Syndrome
NEWTON, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a clinical stage pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with s...
GlobeNewswire · 5d ago
Acer Therapeutics Starts Patient Screening for Phase 3 Edsivo Trial in Vascular Ehlers-Danlos Syndrome
MT Newswires · 5d ago
New Strong Sell Stocks for June 23rd
ACER, PRG, and ALX have been added to the Zacks Rank #5 (Strong Sell) List on June 23, 2022.
Zacks · 06/23 12:14
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 329 companies hit new 52-week lows.
Benzinga · 06/22 16:30
Acer Therapeutics (ACER) Gets CRL for Urea Cycle Disorders Drug
Acer Therapeutics' (ACER) new drug application for ACER-001 to treat urea cycle disorders faces rejection from the FDA. Share price falls 21% following the announcement.
Zacks · 06/22 13:43
No Data
Learn about the latest financial forecast of ACER. Analyze the recent business situations of Acer Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 3 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ACER stock price target is 9.67 with a high estimate of 12.00 and a low estimate of 7.00.
Current 1.280
EPS
Actual
Estimate
-0.51-0.38-0.26-0.13
Institutional Holdings
Institutions: 44
Institutional Holdings: 1.63M
% Owned: 9.19%
Shares Outstanding: 15.31M
TypeInstitutionsShares
Increased
5
104.55K
New
2
832
Decreased
6
126.22K
Sold Out
5
28.94K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.10%
Pharmaceuticals & Medical Research
+0.97%
Key Executives
Non-Executive Chairman/Independent Director
Stephen Aselage
President/Chief Executive Officer/Director
Christopher Schelling
Chief Financial Officer
Harry Palmin
Chief Operating Officer
Tanya Hayden
Chief Human Resource Officer
Bernie Paul
Other
Jefferson Davis
Other
John Klopp
Other
Adrian Quartel
Other
Matthew Seibt
Secretary
Donald Joseph
Independent Director
Jason Amello
Independent Director
John Dunn
Independent Director
Michelle Griffin
No Data
No Data
About ACER
Acer Therapeutics Inc. is a pharmaceutical company, which is focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. The Company’s pipeline includes four programs: ACER-001 (sodium phenylbutyrate), ACER-801 (osanetant), EDSIVO (celiprolol) and ACER-2820 (emetine). ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); ACER-801 (osanetant) for the treatment of induced vasomotor symptoms (iVMS); EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and ACER-2820 (emetine), a host-directed therapy against a variety of viruses, including cytomegalovirus, zika, dengue, ebola and COVID-19.
Webull offers kinds of Acer Therapeutics Inc stock information, including NASDAQ:ACER real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACER stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading ACER stock methods without spending real money on the virtual paper trading platform.